En Es
Categories

Industry News

Intel and Philips Partner to Speed Up Imaging Analysis Using AI

By Medimaging International staff writers
22 Aug 2018

Image: Using Intel Xeon Scalable processors and the OpenVINO toolkit, Intel and Philips tested two healthcare use cases for deep learning inference models (Photo courtesy of iStock).Intel Corporation (Santa Clara, CA, USA) and Royal Philips (Amsterdam, Netherlands) have tested two healthcare use cases for deep learning inference models: one on X-rays of bones for bone-age-prediction modeling and the other on CT scans of lungs for lung segmentation. In these tests, which were conducted using Intel Xeon Scalable processors and the OpenVINO toolkit, the researchers achieved a speed improvement of 188 times for the bone-age-prediction model and 38 times for the lung-segmentation model over the baseline measurements. These tests show that healthcare organizations can implement artificial intelligence (AI) workloads without expensive hardware investments.

The size of medical image files is growing along with the improvement in medical image resolution, with most images having a size of 1GB or greater. More healthcare organizations are using deep learning inference to more quickly and accurately review patient images. AI techniques such as object detection and segmentation can help radiologists identify issues faster and more accurately, which can translate to better prioritization of cases, better outcomes for more patients and reduced costs for hospitals. Deep learning inference applications typically process workloads in small batches or in a streaming manner, which means they do not exhibit large batch sizes. Until recently, graphics processing unit (GPUs) was the prominent hardware solution to accelerate deep learning. By design, GPUs work well with images, but also have inherent memory constraints that data scientists have had to work around when building some models.

Central processing units (CPUs), such as Intel Xeon Scalable processors, do not have such memory constraints and can accelerate complex, hybrid workloads, including larger, memory-intensive models typically found in medical imaging. For a large subset of AI workloads, CPUs can better meet the needs of data scientists as compared to GPU-based systems. Running healthcare deep learning workloads on CPU-based devices offers direct benefits to companies such as Philips as it allows them to offer AI-based services that do not drive up costs for their end customers.

“Intel Xeon Scalable processors appear to be the right solution for this type of AI workload. Our customers can use their existing hardware to its maximum potential, while still aiming to achieve quality output resolution at exceptional speeds,” said Vijayananda J., chief architect and fellow, Data Science and AI at Philips HealthSuite Insights.



E-mail Print
FaceBook Twitter Google+ Linked in

Philips Healthcare

Operates in Diagnostic Imaging Systems, Patient Care and Clinical Informatics, Customer Services, and Home Healthcare with a strong presence in cardio-pulmonary, oncology and women’s health
More info

More articles about Philips Healthcare

09 Nov 2021
Philips Acquires Medical Technology Company Cardiologs to Expand Cardiac Diagnostics and Monitoring Portfolio
Royal Philips (Amsterdam, the Netherlands) has signed an agreement to acquire Cardiologs (Paris, France), a medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology.
Read More
13 Apr 2021
Philips Collaborates with AI Startup Ibex to Accelerate Adoption of AI-Powered Digital Pathology Solutions
Royal Philips (Amsterdam, The Netherlands) and Ibex Medical Analytics (Tel Aviv, Israel) have entered into a strategic collaboration to jointly promote their digital pathology and AI solutions to hospitals, health networks and pathology labs worldwide.
Read More
09 Mar 2021
Philips' Diagnostic X-ray Suite to Incorporate Lunit's AI Software
Philips Healthcare (Amsterdam?, the Netherlands) has entered into a collaboration with Lunit (Seoul, Korea) that will make Lunit's AI software accessible to users of Philips' diagnostic X-ray solutions.
Read More
20 Jan 2021
Philips Acquires Capsule Technologies to Expand Leadership in Patient Care Management Solutions for Hospitals
Royal Philips (Amsterdam, the Netherlands) has signed an agreement to acquire Capsule Technologies, Inc. (Andover, MA, USA), a provider of medical device integration and data technologies for hospitals and healthcare organizations.
Read More
10 Mar 2020
Philips Receives Global AI for Enhanced Radiology Interpretation Company of The Year Award from Frost & Sullivan
 Philips Healthcare (Amsterdam?, Noord-Holland) has been recognized with the 2019 Global Company of the Year Award by Frost & Sullivan, based on its recent analysis of the global market for Artificial Intelligence (AI) for enhanced radiology interpretation market. Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
Read More
05 Apr 2019
Philips Acquires Direct Radiology Teleradiology Platform
Royal Philips is expanding its radiology solutions portfolio with innovative teleradiology services, aimed at addressing the increasing shortage of radiologists, as well as the pressing need to improve access to precision diagnoses.
Read More
30 Oct 2018
Philips Launches Start-Up AI Collaboration Program
Royal Philips has launched its first global start-up collaboration program involving the company’s innovation hubs in Cambridge, US, Eindhoven, the Netherlands, Bangalore, India and Shanghai, China focused on the application of artificial intelligence (AI) in healthcare. The program focuses on the application of AI-based clinical decision support tools, such as image interpretation, analysis and integration, and workflow tools, such as intelligent treatment plans for radiology, ultrasound and oncology.
Read More
25 Jun 2018
Philips Acquires Remote Diagnostic Technologies to Expand Therapeutics
Royal Philips has acquired Remote Diagnostic Technologies, which offers advanced solutions for the pre-hospital market providing monitoring, cardiac therapy and data management. RDT’s portfolio of connected emergency care solutions will complement Philips’ Therapeutic Care business and strengthen its leadership position in the resuscitation and emergency care market. RDT’s acquisition will also strengthen Philips’ ability to innovate, drive digital transformation in healthcare, and enter new markets.
Read More

Additional news

30 Nov 2022
Global Multiparameter Patient Monitoring Systems Market Driven by Rising Chronic Illnesses
An increase in the number of people suffering from chronic illnesses, combined with an ever-growing elderly population, is expected to help the global multiparameter patient monitoring systems market register a CAGR of 5.8% over the 2022-2028 period to reach USD 15.5 billion by 2028.
Read More
23 Nov 2022
Global Visualization Instruments for MIS Market Driven by Increasing Demand for Endoscopy Procedures
The increasing demand for visualization systems for complex surgical procedures, growing demand for minimally invasive surgeries, and rising prevalence of chronic diseases are expected to help the global visualization instruments for minimally invasive surgery (MIS) market register a CAGR of 7.2% between 2022 and 2031 and reach a value of USD 21 billion by 2031.
Read More
11 Nov 2022
Global Diagnostic ECG Market Driven by Increased Incidence of Cardiac Diseases
The rising prevalence of such chronic conditions is necessitating the need for diagnosis and treatment in order to keep track of the patient's daily medical condition and maintain medical records. This, coupled with rising hospitalization of the older population for the treatment of cardiac diseases, has increased the need for electrocardiograph (ECG) diagnosis.
Read More
11 Nov 2022
Radcal to Supply Quality Assurance X-Ray Testing Equipment to West Physics
Radcal Corporation (Monrovia, CA, USA), a leading manufacturer of diagnostic X-ray quality assurance (QA) meters, has reached an agreement with West Physics (Atlanta, GA, USA), one of the largest and most successful Medical Physics groups in the U.S., to supply QA X-ray testing equipment.
Read More
09 Nov 2022
Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling
Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining panels, tissue staining, and imaging and analysis services.
Read More
08 Nov 2022
Global Infusion Pumps Market Driven by Increasing Incidence of Chronic Diseases
Rising demand for ambulatory infusion pumps in home care, increasing incidence of chronic diseases along with a rapid growth of the geriatric population, and growing number of surgical procedures being performed, are driving the growth of the global infusion pumps market. As a result, the market is projected to register a CAGR of 7% from USD 14.7 billion in 2022 to USD 20.5 billion by 2027.
Read More
07 Nov 2022
Mast Group Enters into Multi-Country Distribution Agreement for Nanomix's eLab System
Mast Group Limited (Liverpool, UK) and Nanomix (Emeryville, CA, USA) have entered into a multi-region distribution agreement wherein Mast will market and distribute the Nan?mix eLab system in the UK, Germany, France, Ireland and South Africa.
Read More
07 Nov 2022
AI-Enabled Diagnostic Testing Could Become More Accurate and Reliable than Current Tests
An expanded collaboration between two industry leaders will pave the way for the development of AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.
Read More
01 Nov 2022
Global Infectious Respiratory Disease Diagnostics Market Driven by New Multiplex PCR Tests and POC Products
The global infectious respiratory disease diagnostics market size is expected to reach USD 43.6 billion by 2030, driven by an increase in the prevalence of infectious respiratory diseases and initiatives taken by governments & non-profit organizations to introduce novel & innovative products to address the growing demand.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions